2. Bremnor J.D., Sadovsky R. Evaluation of dysuria in adults. Am Fam Physician 2002;65(8):1589–1596.

3. Hanno P., Nordling J., Fall M. Bladder pain syndrome. Med Clin North Am 2011;95(1):55–73.

4. Richardson D.A. Dysuria and urinary tract infections. Obstet Gynecol Clin North Am 1990;17:881–888.

5. Sommer P., Nielsen K.K., Bauer T., et al. Voiding patterns in men evaluated by a questionnaire survey. Br J Urol 1990;65:155–160.

6. Wyndaele J.J., De Wachter S. The sensory bladder (1): an update on the different sensations described in the lower urinary tract and the physiological mechanisms behind them. Neurourol Urodyn 2008;27(4):274–278.

7. Kulkarni S.K. Antispasmodics – A new perspective. JAMA India 2001;4(8):119–121.

8. Roxburgh C., Cook J., Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2007;(3):CD003190.

9. Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., Weinstein D.The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urol 2008; 54(3): 543–562.

10. Sri Sivalingam, Manoj Monga. Management of Ureteral Stent Discomfort in Contemporary Urology Practice. Urology Practice 1 (2014), 141–145.

11. Deliveliotis C., Chrisofos M., Gougousis E. et al. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006;67:35.

12. Beddingfield R., Pedro R.N., Hinck B. et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 2009; 181: 170.

13. Dellis A.E., Keeley F.X. Jr, Manolas V. et al. Role of a-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology 2014; 83: 56.

14. Nakada S.Y., Jerde T.J., Bjorling D.E. et al. Selective cyclooxygenase-2 inhibitors reduce ureteral contraction in vitro: a better alternative for renal colic? J Urol 2000; 163: 607.

15. Kyungtae Ko, Won Ki Lee, Cheol Young Oh et al. Is A Combination of Antibiotics and Non-Steroidal Anti-Inflammatory Drugs More Beneficial Than Antibiotic Monotherapy For The Treatment of Female Acute Uncomplicated Cystitis? A Randomized Controlled Pilot Study. Female Urology 2018; 15(06):365–369.

16. Gágyor I., Bleidorn J., Kochen M.M., Schmiemann G., Wegscheider K., Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;23;351:h6544.

17. Kulchavenya E. Acute uncomplicated cystitis: is antibiotic unavoidable? Ther Adv Urol 2018;10(9):257–262.

18. Lars Bjerrum, Morten Lindbæk. Which treatment strategy for women with symptoms of urinary tract infection? BMJ 2015; 351:h6888. Published online 2015 Dec 29.

19. Yan H., Wang Y., Sun R., Cui Y. The Efficacy of Antimuscarinics Alone or in Combination with Alpha-Blockers for the Treatment of Ureteral Stent-Related Symptoms: A Systematic Review and Meta-Analysis. Urol Int 2017;99(1):6–13.

20. Gupta O.P., Aggarwal K.K. Role of Phenazopyridine in Urinary Tract Infections. Indian Journal of Clinical Practice 2012; 22(9):437–441.

21. Kinnman E., Nygards E.B., Hansson P. Peripheral alpha–adrenoreceptors are involved in the development of capsaicin induced ongoing and stimulus evoked pain in humans. Pain 1997;69:79–85.

22. Ye Z.Q., Lan R.Z., Yang W.M. et al. Tamsulosin treatment of chronic non-bacterial prostatitis. J. Int. Med. Res. 2008; 36(2):244–252.

23. Lamb A.D., Vowler S.L., Johnston R., Dunn N., Wiseman O.J. Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. BJU Int. 2011;108(11):1894–1902.

24. Yakoubi R., Lemdani M., Monga M., Villers A., Koenig P. Is there a role for alpha-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011;186(3):928–934.

25. Kwon J.K., Cho K.S., Oh C.K., Kang D.H., Lee H., Ham W.S., Choi Y.D., Lee J.Y. The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo. BMC Urol. 2015;24:15–55.

26. Vassilis Pergialiotis, Pantelis Arnos, Michael N Mavros, Eleni Pitsouni, Stavros Athanasiou, Matthew E Falagas. Urinary tract analgesics for the treatment of patients with acute cystitis: where is the clinical evidence? Expert Rev. Anti Infect. Ther 2012; 10(8), 875–879.

27. Jenkins G.L., Hartung W. The Chemistry of Organic Medicinal Products. Uchebnoe posobie. M.: Gosudarstvennoe izdatel’stvo inostrannoi literatury; 1949. Russian (Дженкинс Г.Н, Хартунг У. Химия органических лекарственных препаратов. Учебное пособие. М.: Государственное издательство иностранной литературы; 1949).

28. Ramesh Hotchandani, Aggarwal K.K. Urinary Tract Infections in Women. Indian Journal of Clinical Practice 2012; 23(4):187–192.

29. https://clincalc.com/drugstats/drugs/phenazopyridine. Доступ от 13.12.2018

30. Thomas B.H., Whitehouse L.W., Solomonraj G., Paul C.J. Metabolism and disposition of phenazopyridine in rat. Xenobiotica 1993;23(2):99–105.

31. Naoki Aizawa, Jean-Jacques Wyndaele. Effects of phenazopyridine on rat bladder primary afferent activity, and comparison with lidocaine and acetaminophen. Neurourol. Urodynam 2010;29: 1445–1450.

32. Kirwin T.J., Lowsley A.S., Menning J. The effects of Pyridium in certain urogenital infections. Am J Surg 1943;62:330–335.

33. Zelenitsky S.A., Zhanel G.G. Phenazopyridine in urinary tract infections, Ann Pharmacother. 1996;30(7-8):866–888.

34. Trickett P.C. Ancillary use of phenazopyridine (Pyridium) in urinary tract infections. CUIT Ther Res 1970;12:441–445.

35. Gould S. Clinical comparison of flavoxate and phenazopyridine. Urology 1975;5:612–615.

36. Gilderman L., Hendry D., Patrick K. Evaluation of the efficacy of phenazopyridine Hydrochloride (Formula PD-F-0016) as a urinary analgesic in women with urinary tract infections. FDA’s Dockets Management. Protocol Number: 99-001-P (2001). www.fda.gov

37. Deepalatha C., Deshpande N. A comparative study of phenazopyridine (pyridium) and cystone as short-term analgesic in uncomplicated urinary tract infection. Int J Pharm Pharm Sci 2011;3(Suppl 2):224–226.

38. Marcelín-Jiménez G., Ángeles A.P., Martínez-Rossier L. et al. Ciprofloxacin Bioavailability is Enhanced by Oral Co-Administration with Phenazopyridine Clin. Drug Investig. 2006; 26:323

39. Kasymov A.A. Use of Uropirin for treatment of patients with inflammatory diseases of lower urinary tract. Medicina 2012;5:3. Russian (Касымов А.А.Применение препарата Уропирин в лечении больных с воспалительными заболеваниями нижних мочевых путей. Медицина 2012;5:39).

40. Fischer K.M., Louie M. Ureteral Stent Discomfort and Its Management.P. Curr Urol Rep, 2018; 19: 64.

41. Norris R.D., Sur R.L., Springhart W.P., Marguet C.G., Mathias B.J., Pietrow P.K., Albala D.M., Preminger G.M. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology 2008;71(5):792–795.

42. Nazarko L. Bladder pain from indwelling urinary catheterization: case study. Br J Nurs 2007;16(9):511-2,514.

43. Yu C.H., Wang C.H., Chang C.C. Chocolate colored blood with normal artery oxygen: methemoglobinemia related to phenazopyridine. Am. J. Med. Sci 2011; 341(4): 337.

44. Haigh C., Dewar J.C. Multiple adverse effects of pyridium: a case report. South. Med. J 2006; 99(1): 90–92.

45. Vega J. Acute renal failure caused by phenazopyridine. Rev. Med. Chil 2003;131(5):541–544.

46. Rivas R., Martínez Torres A., Bohorques R., Martínez Albelo I. Acute kidney failure caused by phenazopyridine overdose. Nefrologia 2001; 21(1):97–98.

47. Siddiqui M.A. Chronic severe hemolytic anemia from phenazopyridine. Ann. Intern. Med 1995; 122(2): 156–157.

48. Thomas R.J., Doddabele S., Karnad A.B. Chronic severe hemolytic anemia related to surreptitious phenazopyridine abuse. Ann. Intern. Med 1994;121(4):308.

49. Shahani L., Sattovia S. Acquired methaemoglobinaemia related to phenazopyridine ingestion. BMJ Case Reports. 2012;2012.

50. Shatila W., Clark A. Unexplained hypoxia in a woman presenting with acute on chronic abdominal pain. Am J Med. 2013;126:e1–2.

51. Daly J.S., Hultquist D.E., Rucknagel D.L. Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase. J Med Genet 1983;20:307–309.

52. Banimahd F., Loo, T., Amin M., Ahadiat O. R., Chakravarthy B., Lotfipour S. A Rare but Important Clinical Presentation of Induced Methemoglobinemia. The western journal of emergency medicine 2016; 17(5): 627–629.

53. Holmes I., Berman N., Domingues V. Acute Renal Failure and Jaundice without methemoglobinemia in a Patient with Phenazopyridine Overdose: Case Report and Review of the Literature. Case Rep Nephrol. 2014;2014:845372.

54. Nathan D.M., Siegel A.J., Bunn H.F. Acute methemoglobinemia and hemolytic anemia with phenazopyridine: possible relation to acute renal failure. Arch Intern Med 1977;137(11):1636–1638.

55. Christensen C.M., Farrar H.C., Kearns G.L. Protracted methemoglobinemia after phenazopyridine overdose in an infant. J Clin Pharmacol 1996;36(2):112–116.

56. Gold N.A., Bithoney W.G. Methemoglobinemia due to ingestion of at most three pills of pyridium in a 2-year-old: case report and review. J Emerg Med 2003;25(2):143–148.

57. Jeffery W.H., Zelicoff A.P., Hardy W.R. Acquired methemoglobinemia and hemolytic anemia after usual doses of phenazopyridine. Drug Intell Clin Pharm 1982;16(2):157–159.

58. Gavish D., Knobler H., Gottehrer .N, Israeli A., Kleinman Y. Methemoglobinemia, muscle damage and renal failure complicating phenazopyridine overdose. Isr J Med Sci 1986;22(1):45–47.

59. Sand R.E., Edelmann C.M. Jr. Pyridium-induced methemoglobinemia. Report of a case. J Pediatr 1961;58:845–48.

60. Truman T.L., Dallessio J.J., Weibley R.E. Life-threatening Pyridium Plus intoxication: a case report. Pediatr Emerg Care 1995;11(2):103–16.

61. Zimmerman R.C., Green E.D., Ghurabi W.H., Colohan D.P. Methemoglobinemia from overdose of phenazopyridine hydrochloride. Ann Emerg Med 1980;9(3):147–149.

62. Landman J., Kavaler E., Waterhouse R.L. Jr. Acquired methemoglobinemia possibly related to phenazopyridine in a woman with normal renal function. J Urol 1997;158(4):1520–1521.

63. Conroy J.M., Baker J.D. 3rd, Martin W.J., Bailey M.K., Dorman B.H. Acquired methemoglobinemia from multiple oxidants. South Med J 1993;86(10):1156–1159.

64. Randazzo G.P., Ford E.A., Glauser F.L. Methemoglobinemia caused by acute overdosage of phenazopyridine. West J Med 1975; 122(5) 427–429.

65. Crawford S.E., Moon A.E. Jr, Panos T.C., Hooks C.A. Methemoglobinemia associated with pyridium administration; report of a case. J Am Med Assoc 1951 5;146(1):24–25.

66. Lee M., Bozzo P., Einarson A., Koren G. Urinary tract infections in pregnancy. Can Fam Physician 2008;54(6):853–854.